Battle for weight-loss supremacy shifts from jabs to pills
Novo Nordisk’s Wegovy tablet offers Danish drugmaker window to win back market share from Eli Lilly
Related reading
Triple dose of Novo Nordisk drug delivers 19% weight loss in trials
Danish pharma group seeks to broaden options and stay competitive with Eli Lilly
Eli Lilly wins US approval for weight-loss drug in pill form
New drug Foundayo sets up battle with Novo Nordisk for oral obesity drugs
Novo Nordisk weight-loss drug wins US approval as a daily pill
Shares in Danish company rise as drugmaker secures lead in oral obesity treatment
Weight-loss wars: $10bn hostile battle pits Pfizer against Novo Nordisk
Two groups fight for edge in one of the most lucrative drug classes in pharmaceutical industry history
Novo Nordisk faces more gloom from price cuts in crowded anti-obesity drugs…
Danish group’s challenges mount despite winning reprieve after Hims & Hers withdraws plan to sell copycat Wegovy pill
Weight-loss drugs and Mars bars: Novo Nordisk’s comeback bid
The maker of Wegovy and Ozempic wants to learn lessons from consumer groups to crack the US market